Koga Kenjiro, Kawamura Mayuri, Iwase Hiroshi, Yoshikawa Nobuji
Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa.
Drug Des Devel Ther. 2013 Oct 21;7:1235-43. doi: 10.2147/DDDT.S51638. eCollection 2013.
The purpose of this study was to evaluate absorption and elimination from the gastrointestinal tract of glycyrrhizic acid diethyl ester (GZ-DE) which was prepared as a prodrug of glycyrrhizic acid (a poorly absorbed compound) in rats.
After the GZ-DE solution was administered via the intravenous, intraduodenal, intraileal, and stomach routes, GZ-DE and GZ concentrations in bile were determined by high-performance liquid chromatography. The stability of GZ-DE was estimated from residual GZ-DE and GZ produced in GZ-DE solutions prepared with distilled water, a pH 1.2 solution, 0.9% NaCl solution, and phosphate-buffered solution (pH 7.4) at 37°C.
GZ-DE was eliminated into bile by the pharmacokinetic parameters of apparent distribution rate constant (4.56 ± 0.36 per hour) and apparent elimination rate constant (0.245 ± 0.042 per hour). After intravenous and intraduodenal administration of GZ-DE, the concentration ratio of GZ-DE to GZ in bile was approximately 4:1, and the bioavailability of GZ containing GZ-DE was three-fold higher compared with the bioavailability of GZ after intraduodenal administration. GZ-DE was immediately precipitated in pH 1.2 solution and was converted to GZ by hydrolysis in pH 7.4 solution.
Improvement of intestinal absorption of GZ was made possible by administration of GZ-DE into the intestine where absorption of GZ is lower than in the strong acidic environment of the stomach. However, because the elimination rate in bile simulated from kinetic parameters of GZ-DE was higher than the conversion rate from GZ-DE to GZ by hydrolysis, it is thought that the availability of GZ as a revolutionary prodrug was not high from the viewpoint of bioavailability of GZ in the liver by intestinal administration of GZ-DE.
本研究旨在评估甘草酸二乙酯(GZ - DE)在大鼠体内作为甘草酸(一种吸收较差的化合物)的前药从胃肠道的吸收和消除情况。
通过静脉、十二指肠内、回肠内和胃内途径给予GZ - DE溶液后,采用高效液相色谱法测定胆汁中GZ - DE和GZ的浓度。在37℃下,用蒸馏水、pH 1.2溶液、0.9%氯化钠溶液和磷酸盐缓冲溶液(pH 7.4)制备的GZ - DE溶液中,根据残留的GZ - DE和产生的GZ来估计GZ - DE的稳定性。
根据表观分布速率常数(每小时4.56±0.36)和表观消除速率常数(每小时0.245±0.042)的药代动力学参数,GZ - DE被排入胆汁。静脉内和十二指肠内给予GZ - DE后,胆汁中GZ - DE与GZ的浓度比约为4:1,含GZ - DE的GZ的生物利用度比十二指肠内给予GZ后的生物利用度高3倍。GZ - DE在pH 1.2溶液中立即沉淀,并在pH 7.4溶液中通过水解转化为GZ。
通过将GZ - DE给予肠道,使GZ的肠道吸收得到改善,因为在肠道中GZ的吸收低于胃的强酸性环境。然而,由于从GZ - DE的动力学参数模拟的胆汁消除率高于GZ - DE通过水解转化为GZ的转化率,从肠道给予GZ - DE后肝脏中GZ的生物利用度观点来看,认为GZ作为一种新型前药的有效性不高。